Advertisement

FDA Approves Novel Insomnia Drug — Physician’s First Watch

Medical News |
August 15, 2014

FDA Approves Novel Insomnia Drug

By Kristin J. Kelley

Edited by André Sofair, MD, MPH, and William E. Chavey, MD, MS

Suvorexant tablets (marketed as Belsomra) have been approved to treat insomnia, the FDA announced on Wednesday. The drug is the first approved orexin receptor antagonist — orexin helps regulate wakefulness.

Like other sleep aids, Suvorexant is a Schedule-IV controlled substance, as it may lead to dependence. In addition, it carries a risk for behaviors such as driving, eating, having sex, and making phone calls while not fully awake. It will be available in 5-, 10-, 15- and 20-mg doses; the lower the dose, the lower the risk for common side effects like next-day drowsiness. Patients should not take more than 20 mg per day.

The approval is based on data from three randomized trials of some 500 total patients. Those who took suvorexant fell asleep faster and woke up less during the night than those given placebo.

Reader Comments (1)

Dr. Deepak bharti Physician, Internal Medicine, Gmc jammu

gr8 source of gaining and update ur knowledge

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement